Cargando…

Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

PURPOSE: The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) and fixed duration (FD cohort). We report tumor debulking an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barr, Paul M., Tedeschi, Alessandra, Wierda, William G., Allan, John N., Ghia, Paolo, Vallisa, Daniele, Jacobs, Ryan, O'Brien, Susan, Grigg, Andrew P., Walker, Patricia, Zhou, Cathy, Ninomoto, Joi, Krigsfeld, Gabriel, Tam, Constantine S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Briefs: Clinical Trial Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561555/ https://www.ncbi.nlm.nih.gov/pubmed/35939599 http://dx.doi.org/10.1158/1078-0432.CCR-22-0504

Ejemplares similares

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia
por: Allan, John N., et al.
Publicado: (2023)

Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
por: Moreno, Carol, et al.
Publicado: (2023)

Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
por: Wierda, William G., et al.
Publicado: (2021)

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL): 4-Y FOLLOW-UP FROM FD COHORT OF PHASE 2 CAPTIVATE STUDY
por: Ghia, Paolo, et al.
Publicado: (2023)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Barrientos, J. C., et al.
Publicado: (2022)

Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019)

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
por: Davids, Matthew S., et al.
Publicado: (2021)

Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
por: Jones, Jeffrey A., et al.
Publicado: (2017)

Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
por: Barr, Paul M., et al.
Publicado: (2022)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023)

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia
por: Yi, Xue, et al.
Publicado: (2022)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

Electrocardiographic Changes Associated With Ibrutinib Exposure
por: Fradley, Michael G., et al.
Publicado: (2020)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Fulminant Acanthamoeba castellanii Encephalitis in an Ibrutinib-Treated Patient
por: Crothers, Jessica W, et al.
Publicado: (2020)

Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III Innovate(TM) Trial
por: Trotman, Judith, et al.
Publicado: (2021)

Ibrutinib-induced acute kidney injury via interstitial nephritis
por: Markóth, Csilla, et al.
Publicado: (2021)

Breakthrough Invasive Fungal Infection After Coadministration of Venetoclax and Voriconazole
por: Hall, Victoria G, et al.
Publicado: (2023)

Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib
por: Messina, Julia A., et al.
Publicado: (2017)

Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients
por: Protin, Caroline, et al.
Publicado: (2019)

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial
por: Seymour, John F., et al.
Publicado: (2023)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
por: Chowdhury, Subir Roy, et al.
Publicado: (2021)

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL
por: Jain, Nitin, et al.
Publicado: (2022)

Entirely irrelevant distractors can capture and captivate attention
por: Forster, Sophie, et al.
Publicado: (2011)

Molecular detection of Brucella abortus in wild and captive felids
por: Kagueyama, Francielle Cristina, et al.
Publicado: (2022)

Molecular evidence of Monocercomonas and Acanthamoeba in the feces of captive reptiles
por: Tuska-Szalay, Barbara, et al.
Publicado: (2022)

A Tec kinase BTK inhibitor ibrutinib promotes maturation and activation of dendritic cells
por: Natarajan, Gayathri, et al.
Publicado: (2016)

What Influences the Choice of Ibrutinib–Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?
por: Bravaccini, Sara, et al.
Publicado: (2020)

Mechanism of inulin in colic and gut microbiota of captive Asian elephant
por: Bo, Tingbei, et al.
Publicado: (2023)

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax
por: Figueroa, Rocio, et al.
Publicado: (2020)

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
por: Wang, Michael, et al.
Publicado: (2021)

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
por: Hillmen, Peter, et al.
Publicado: (2019)

Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study
por: Coutre, Steven E, et al.
Publicado: (2022)

Eternal nodules to fix the nitrogen issue: Promotion of soybean nodule senescence by a NAC/CYP module
por: Doll, Nicolas M
Publicado: (2023)

First confirmed complete incubation of a flapper skate (Dipturus intermedius) egg in captivity
por: Benjamins, Steven, et al.
Publicado: (2021)

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
por: Munir, Talha, et al.
Publicado: (2023)

The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
por: Li, Zhaodong, et al.
Publicado: (2018)

PB1863: BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)
por: Mato, A. R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q4oltaerdm04ci3lbvk5r5t8p8